Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
NCT02741856
Unknown
Research has shown that increasing the dose of radiotherapy improves outcomes in patients with lung and head and neck cancers. This study aims to see whether this is also the case for patients with tumour of the oesophagus. This trial will compare the effects of the standard dose of radiotherapy to a higher dose whilst closely monitoring the side effects. A comparison will also be made regarding the effects of the standard drugs used in chemotherapy (cisplatin and capecitabine) with an alternat... Read More
Gender:
ALL
Ages:
17 years and above
Trial Updated:
10/24/2018
Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +25 locations
Conditions: Oesophageal Cancer
Register for Updates
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
NCT02350712
Completed
The purpose of this study is to test a study drug called patritumab. Patritumab may work when combined with other medications that are approved in the UK for treating Squamous Cell Carcinoma of the Head and Neck (SCCHN), called cetuximab, cisplatin or carboplatin. It is hoped that patritumab may have some benefit in treating patients with cancer. This study will help identify how much patritumab can be given in combination with cetuximab, and cisplatin or carboplatin. This study will show how sa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2018
Locations: The Royal Marsden Hospital, Sutton, Surrey +2 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
NCT00458913
Completed
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib together with cispla... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/11/2018
Locations: Royal Marsden - Surrey, Sutton, England
Conditions: Malignant Mesothelioma
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00003888
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combinati... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/06/2018
Locations: Landeskrankenhaus/Universitatskliniken Graz, Graz, Not set +43 locations
Conditions: Head and Neck Cancer
Register for Updates
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
NCT00652132
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer. PURPOSE: This randomized phase III trial is s... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
05/24/2018
Locations: Birmingham Children's Hospital, Birmingham, England +15 locations
Conditions: Liver Cancer, Ototoxicity
Register for Updates
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
NCT00215644
Completed
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Participants invited to take part have metastatic cancer of the esophagus (gullet) or stomach.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2018
Locations: Research Site, Essen, Not set +21 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
NCT01719835
Unknown
This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2018
Locations: Royal Marsden NHS Foundation Trust - London and Surrey, London, Not set
Conditions: Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic Gamma/ Delta T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
Register for Updates
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
NCT01809210
Completed
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC. The study has been designed to allow an investigation of the optimal dose of selumetinib in combination with various standard first line double-platinum chemotherapy regimens. Initial assessment will be based on tolerability of selumetinib in combination with one or more selected regimens that are considered to be tole... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/12/2018
Locations: Research Site, Glasgow, Not set +3 locations
Conditions: Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Register for Updates
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
NCT02280993
Unknown
To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse is expected to induce a significantly higher (metabolic) complete remission (CR) rate prior to consolidation with BEAM, as judged by FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose)-PET negativity. This will be compared with published data on DHAP salvage only. Increasing the metabolic CR rate prior to co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2018
Locations: Rigshospitalet, Copenhagen, Not set +12 locations
Conditions: Hodgkin Lymphoma, Refractory, Relapse
Register for Updates
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
NCT00949650
Completed
This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2018
Locations: Highlands Oncology Group, Fayetteville, Arkansas +132 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Register for Updates
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
NCT01090466
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine hydrochloride and cisplatin together with temsirolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of temsirol... Read More
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
02/02/2018
Locations: Leeds Cancer Centre at St. James's University Hospital, Leeds, England
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Register for Updates
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
NCT00678977
Completed
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen(OTR) of pazopanib in combination with gemcitabine (Arm A) or pazopanib, gemcitabine, and cisplatin (Arm B) in patients with advanced solid tumors. Patients will be enrolled in cohorts of 3 to receive escalating doses of pazopanib and gemcitabine or pazopanib, gemcitabine and cisplatin. Dose escalation schemas for each study arm are described in the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2017
Locations: GSK Investigational Site, Essen, Nordrhein-Westfalen +1 locations
Conditions: Lung Cancer, Non-Small Cell
Register for Updates